Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last761 to 780 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Bleeding Complication | 869 of 6,110 834 of 6,101 | 0.6 points -0.7 to 1.8 | 12,211 | NCT02984384 PREVENTion of Clot in Orthopaedic Trauma |
| Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Wound Complication | 14 of 6,110 8 of 6,101 | 0.1 points -0.1 to 0.3 | 12,211 | NCT02984384 PREVENTion of Clot in Orthopaedic Trauma |
| Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: deaths from any cause | 45 of 6,110 47 of 6,101 | -0.0 points -0.3 to 0.3 | 12,211 | NCT02984384 PREVENTion of Clot in Orthopaedic Trauma |
| Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Deep Vein Thrombosis | 103 of 6,110 151 of 6,101 | -0.8 points -1.3 to -0.3 | 12,211 | NCT02984384 PREVENTion of Clot in Orthopaedic Trauma |
| Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: serious adverse events | 260 of 6,110 324 of 6,101 | -1.1 points -1.8 to -0.3 | 12,211 | NCT02984384 PREVENTion of Clot in Orthopaedic Trauma |
| Evacetrapib vs Placebo: Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke | 437 of 6,038 453 of 6,054 | -0.2 points -1.2 to 0.7 | 12,092 | NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease |
| Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA | 857 of 6,038 867 of 6,054 | -0.1 points -1.4 to 1.1 | 12,092 | NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease |
| Evacetrapib vs Placebo: Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA) | 779 of 6,038 776 of 6,054 | 0.1 points -1.1 to 1.3 | 12,092 | NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease |
| Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA | 571 of 6,038 570 of 6,054 | 0.0 points -1.0 to 1.1 | 12,092 | NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease |
| Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization | 690 of 6,038 691 of 6,054 | 0.0 points -1.1 to 1.1 | 12,092 | NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease |
| Evacetrapib vs Placebo: serious adverse events | 2,306 of 6,036 2,341 of 6,052 | -0.5 points -2.2 to 1.3 | 12,088 | NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease |
| Rivaroxaban 10 mg or 7.5 mg vs Placebo: deaths from any cause | 115 of 6,007 126 of 6,012 | -0.2 points -0.7 to 0.3 | 12,019 | NCT02111564 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients |
| Rivaroxaban 10 mg or 7.5 mg vs Placebo: serious adverse events | 475 of 6,007 493 of 6,012 | -0.3 points -1.3 to 0.7 | 12,019 | NCT02111564 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients |
| D-QIV vs Control: serious adverse events | 217 of 6,006 201 of 6,012 | 0.3 points -0.4 to 0.9 | 12,018 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| Lorcaserin 10 mg vs Placebo: deaths from any cause | 219 of 5,995 202 of 5,992 | 0.3 points -0.4 to 0.9 | 11,987 | NCT02019264 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors |
| Lorcaserin 10 mg vs Placebo: serious adverse events | 1,974 of 5,995 2,021 of 5,992 | -0.8 points -2.5 to 0.9 | 11,987 | NCT02019264 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors |
| ZOSTAVAX™ vs Placebo: serious adverse events | 340 of 5,979 300 of 5,990 | 0.7 points -0.1 to 1.5 | 11,969 | NCT00550745 ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) |
| Idiopathic Pulmonary Fibrosis (IPF) Cohort vs Non Idiopathic Pulmonary Fibrosis (IPF) Cohort: Sustained Oxygen Therapy Use Within the First 12 Months of Follow-up | 967 of 1,339 4,973 of 10,592 | 25.3 points 22.6 to 27.8 | 11,931 | NCT05957198 Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease |
| Intervention Arm vs Placebo Arm: Maternal Outcome 4 - Incidence of Maternal Mortality | 9 of 5,958 12 of 5,948 | -0.1 points -0.2 to 0.1 | 11,906 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: Fetal Outcome 5 - Incidence of Spontaneous Abortion | 134 of 5,956 152 of 5,946 | -0.3 points -0.9 to 0.2 | 11,902 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=39
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02984384-8c8e48ee",
"title": "Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Bleeding Complication",
"summary": "869 of 6110 against 834 of 6101; risk difference 0.6 points, 95% interval -0.7 to 1.8; NCT02984384, PREVENTion of Clot in Orthopaedic Trauma",
"record": "/library/comparisons/NCT02984384-8c8e48ee",
"nct_id": "NCT02984384",
"kind": "outcome",
"participants": 12211,
"risk_difference": {
"value": 0.005526957427761964,
"lower": -0.0067662165883062755,
"upper": 0.017819825217260304
},
"group_1": "869 of 6,110",
"group_2": "834 of 6,101",
"difference": "0.6 points",
"interval": "-0.7 to 1.8",
"trial_title": "PREVENTion of Clot in Orthopaedic Trauma"
},
{
"id": "NCT02984384-d2128428",
"title": "Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Wound Complication",
"summary": "14 of 6110 against 8 of 6101; risk difference 0.1 points, 95% interval -0.1 to 0.3; NCT02984384, PREVENTion of Clot in Orthopaedic Trauma",
"record": "/library/comparisons/NCT02984384-d2128428",
"nct_id": "NCT02984384",
"kind": "outcome",
"participants": 12211,
"risk_difference": {
"value": 0.0009800652464743108,
"lower": -0.0005950680566740171,
"upper": 0.002660792865415331
},
"group_1": "14 of 6,110",
"group_2": "8 of 6,101",
"difference": "0.1 points",
"interval": "-0.1 to 0.3",
"trial_title": "PREVENTion of Clot in Orthopaedic Trauma"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=40",
"request_id": "Fkm66ugtT3285Ris"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant